Title

Does a single dose of intravenous dexamethasone reduce symptoms in emergency department patients with low back pain and Radiculopathy (SEBRA)? A double-blind randomised controlled trial

Date of this Version

8-13-2014

Document Type

Journal Article

Publication Details

Citation only

Balakrishnamoorthy, R., Horgan, I., Perez, S., Steele, M. C., & Keijzers, G. B. (2014). Does a single dose of intravenous dexamethasone reduce symptoms in emergency department patients with low back pain and Radiculopathy (SEBRA)? A double-blind randomised controlled trial. Emergency Medicine Journal.

Access the journal

© Copyright, The Authors, 2014

2014 HERDC Submission

ISSN

1472-0205

Abstract

Objective To assess the effect of a single dose of intravenous dexamethasone in addition to routine treatment on visual analogue scale (VAS) pain scores at 24 h in emergency department (ED) patients with low back pain with radiculopathy (LBPR). Methods Double-blind randomised controlled trial of 58 adult ED patients with LBPR, conducted in one tertiary and one urban ED. The intervention was 8 mg of intravenous dexamethasone (or placebo) in addition to current routine care. The primary outcome was the change in VAS pain scores between presentation and 24 h. Secondary outcomes included VAS pain scores at 6 weeks, ED length of stay (EDLOS), straight leg raise (SLR) angles and Oswestry functional scores. Results Patients treated with dexamethasone had a 1.86 point (95% CI 0.31 to 3.42, p=0.019) greater reduction in VAS pain scores at 24 h than placebo (dexamethasone: -2.63 (95% CI -3.63 to -1.63) versus placebo: -0.77 (95% CI -2.04 to 0.51)). At 6 weeks, both groups had similar significant and sustained decrease in VAS scores compared with baseline. Patients receiving dexamethasone had a significantly shorter EDLOS (median: 3.5 h vs 18.8 h, p=0.049) and improved SLR angle at discharge (14.7°, p=0.040). There was no difference in functional scores. Conclusions In patients with LBPR, a single dose of intravenous dexamethasone in addition to routine management improved VAS pain scores at 24 h, but this effect was not statistically significant at 6 weeks. Dexamethasone may reduce EDLOS and can be considered as a safe adjunct to standard treatment.

This document is currently not available here.

Share

COinS
 

This document has been peer reviewed.